RAI-20

RAI-20 (H018) is an orally bioavailable dual inhibitor of JAK1 and JAK2, with IC50 values of 15.1 and 22.7 nM, respectively. It exhibits excellent pharmacokinetic properties, including plasma stability, systemic exposure, and a prolonged half-life. In a collagen-induced arthritis rat model, RAI-20 demonstrates significant anti-inflammatory and anti-arthritic activities, effectively reducing paw swelling volume and the arthritis index. RAI-20 serves as a useful compound for research into the pathogenesis of rheumatoid arthritis.